Precision BioSciences Inc (DTIL)

[swampboots]

DTIL 1.53:
"Live In Play®
Updated: 18-Jul-22 07:37 ET
DTIL: Precision BioSciences received the $50 mln upfront cash payment from Novartis (NVS) under the Collaboration and License Agreement on July 12 (1.42)
The Company expects that as of July 12, 2022, this cash payment, together with its existing cash and cash equivalents, expected operational receipts, and available credit, will be sufficient to fund its operating expenses and capital expenditure to year-end 2024.
Although it has not finalized its full financial results for the quarter ended June 30, 2022, the Company expects to report that it had approximately $184 million in cash and cash equivalents as of June 30, 2022 including receipts of $25 million from Novartis' equity investment in the Company and the June 2022 underwritten offering of the Company's common stock. This amount does not include $50 million in cash received from Novartis subsequent to June 30, 2022."